Tempus AI (NASDAQ:TEM) Director Sells $21,981.70 in Stock

Key Points

• Director David Epstein sold 370 shares on Feb. 2 at an average price of $59.41 for $21,981.70, leaving him with 26,051 shares (a 1.4% reduction); the transaction was disclosed in an SEC Form 4 filing.
• Tempus shares fell 4.3% to $53.55 on heavy volume (~9.6M vs. a 5.76M average). The company reported strong revenue growth (+84.7% YoY and a revenue beat) but remains unprofitable with negative margins and ROE, and analysts' consensus is a "Hold" with an average target of $87.20.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 370 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $59.41, for a total transaction of $21,981.70. Following the sale, the director directly owned 26,051 shares of the company's stock, valued at approximately $1,547,689.91. This trade represents a 1.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Tempus AI Stock Down 4.3%

Shares of Tempus AI stock traded down $2.42 during trading on Wednesday, reaching $53.55. 9,600,266 shares of the company traded hands, compared to its average volume of 5,760,559. The firm has a market capitalization of $9.53 billion, a PE ratio of -45.00 and a beta of 5.22. Tempus AI, Inc. has a 1-year low of $36.22 and a 1-year high of $104.32. The company has a 50 day moving average price of $67.79 and a 200-day moving average price of $74.07. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business's revenue was up 84.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.46) earnings per share. As a group, equities research analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of TEM. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock valued at $605,772,000 after purchasing an additional 817,014 shares during the last quarter. GC Wealth Management RIA LLC purchased a new position in Tempus AI during the fourth quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 1.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company's stock worth $206,960,000 after purchasing an additional 41,728 shares in the last quarter. Voloridge Investment Management LLC increased its stake in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after buying an additional 1,039,176 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Tempus AI by 0.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock valued at $117,523,000 after buying an additional 5,375 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Needham & Company LLC increased their price target on Tempus AI from $70.00 to $100.00 and gave the stock a "buy" rating in a report on Wednesday, November 5th. Piper Sandler cut their target price on Tempus AI from $105.00 to $80.00 and set a "neutral" rating on the stock in a report on Tuesday, November 11th. Morgan Stanley upped their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a report on Monday, December 1st. JPMorgan Chase & Co. reduced their price objective on shares of Tempus AI from $85.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, December 15th. Finally, Canaccord Genuity Group lowered their target price on shares of Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $87.20.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.